Lessons from "real life experience" of rifaximin use in the management of recurrent hepatic encephalopathy.

ABSTRACT: BACKGROUND:Hepatic encephalopathy (HE) is a major complication of cirrhosis with independent prognostic significance. The current management of HE is mainly based on lactulose. Rifaximin has been shown to decrease the risk of HE recurrence in patients with episodic forms. HE can also be persistent. However, there is no drug support recommendation for rifaximin use in this setting. AIM:To assess the effectiveness of rifaximin in the management of recurrent episodes of HE and recurrent acute exacerbations on persistent HE, in "real life conditions". METHODS:In this retrospective study, using a within-subjects design, we collected data of patients treated with rifaximin for HE in two liver diseases centers, during the six-month period before and during the six-month period after the initiatio

SUBMITTER: Chautant F 

PROVIDER: S-EPMC6946626 | biostudies-literature | 2020 Jan

REPOSITORIES: biostudies-literature